Both perimenstrual and nonperimenstrual migraine days respond to anti‐calcitonin gene‐related peptide (receptor) antibodies

Abstract

Our findings support prophylactic use of anti-CGRP (receptor) antibodies for women with menstrual migraine, as this leads to consistent reductions in number of migraine days during the entire menstrual cycle.